Loading
A phase 2 trial of Trastuzumab, Trastuzumab rezetecan and Trastuzumab deruxtecan in advanced solid tumours, run by Jiangsu HengRui Medicine Co., Ltd., now recruiting.
A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer is a phase 2 interventional study registered as NCT07497386 by Jiangsu HengRui Medicine Co., Ltd., with 150 participants planned, started 2026-04-28 and due to reach its primary completion in 2028-06. Interventions recorded: Trastuzumab Rezetecan for Injection and Trastuzumab Deruxtecan for Injection.
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Topoisomerase-I inhibitors (and ADC payloads), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Topoisomerase-I inhibitors (and ADC payloads), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Trastuzumab, Topoisomerase-I inhibitors (and ADC payloads) and the tag pipeline.
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Trastuzumab, Topoisomerase-I inhibitors (and ADC payloads) and the tag pipeline.
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Trastuzumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Topoisomerase-I inhibitors (and ADC payloads), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Topoisomerase-I inhibitors (and ADC payloads), Monoclonal antibodies and the tag pipeline.